Vanda Pharmaceuticals Inc.
VNDA
$8.81
-$0.48-5.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 57.22M | 56.26M | 52.59M | 50.04M | 53.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.22M | 56.26M | 52.59M | 50.04M | 53.19M |
| Cost of Revenue | 3.83M | 2.95M | 2.74M | 3.52M | 2.59M |
| Gross Profit | 53.38M | 53.30M | 49.85M | 46.52M | 50.60M |
| SG&A Expenses | 62.98M | 60.27M | 64.62M | 50.08M | 39.28M |
| Depreciation & Amortization | 1.75M | 1.75M | 1.75M | 1.75M | 1.75M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.57M | 87.54M | 91.09M | 91.07M | 63.46M |
| Operating Income | -40.35M | -31.28M | -38.50M | -41.03M | -10.28M |
| Income Before Tax | -38.00M | -28.39M | -34.89M | -37.37M | -6.50M |
| Income Tax Expenses | 103.19M | -5.80M | -7.68M | -7.87M | -1.59M |
| Earnings from Continuing Operations | -141.19M | -22.59M | -27.21M | -29.49M | -4.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.19M | -22.59M | -27.21M | -29.49M | -4.91M |
| EBIT | -40.35M | -31.28M | -38.50M | -41.03M | -10.28M |
| EBITDA | -38.30M | -29.23M | -36.49M | -39.05M | -8.31M |
| EPS Basic | -2.39 | -0.38 | -0.46 | -0.50 | -0.08 |
| Normalized Basic EPS | -0.42 | -0.30 | -0.37 | -0.40 | -0.14 |
| EPS Diluted | -2.39 | -0.38 | -0.46 | -0.50 | -0.09 |
| Normalized Diluted EPS | -0.42 | -0.30 | -0.37 | -0.40 | -0.14 |
| Average Basic Shares Outstanding | 59.10M | 59.09M | 58.99M | 58.53M | 58.31M |
| Average Diluted Shares Outstanding | 59.10M | 59.09M | 58.99M | 58.53M | 58.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |